Chemical industry – Page 92
-
-
Business
TB drug milestone for bedaquiline
First TB drug with a new mechanism of action for 40 years wins approval
-
Business
Clariant sells business bundle for CHF500m
Textile, paper and emulsion businesses to go to US investment firm
-
Business2012 pharma industry roundup
What were the bigger stories? And how did the industry fare overall?
-
OpinionFear of the unknown
How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe
-
Business
Gilead buys YM for $510m
Deal gives Gilead access to Janus kinase inhibitor CYT387 for the treatment of myelofibrosis
-
Business
AkzoNobel sells $1bn chunk of paints business
North American decorative paints business was responsible for 7% of total AkzoNobel sales in 2011, amounting to $1.5 billion
-
Business
Single EU patent agreed for 2014
European commission says long awaited single patent will cut cost of filing by 87%
-
Business
BP shifting ethanol focus to Brazil
Company to invest $350 million to expand production from sugarcane in Brazil
-
Business
Pfizer's lost gold
A stash of gold dust bought for $700,000 last year has gone missing from a Pfizer lab in St Louis, Missouri, US
-
Business
EU companies increasing R&D
Difficult economic climate has not diminished EU enthusiasm for R&D
-
Business
Mango and Zara sign up to 'detox' plan
Greenpeace campaign to remove hazardous chemicals from the clothing industry is garnering big name support
-
Business
Return on drug R&D dropping
The pharma industry is getting less and less return on investment in R&D but trend seems to be bottoming out
-
Business
Baxter to pay $4bn for dialysis firm
Gambro makes products for hemodialysis and continuous renal replacement therapy
-
Business
Drug R&D costs rising
Review from UK consultancy suggests ten-fold increase in per medicine R&D costs over last 30 years
-
Business
GSK expands in India and Nigeria
Company has struck deals to increase ownership of subsidiaries
-
Business
Lignin to lead bio-based chemicals?
Report says bio-polymer could become a commercial opportunity within three years
-
OpinionFull disclosure?
The pharma industry should be more open with its trial data, says Derek Lowe
-
Business
Roche and the Tamiflu data
Company position on access to data for antiviral Tamiflu (oseltamivir) tablets could be softening
-
Business
Solvay launches €300,000 chemistry prize
To recognise science that could ‘shape tomorrow’s chemistry and help human progress’